Resistance to the Sterne strain of B. anthracis: phagocytic cell responses of resistant and susceptible mice

Microbial Pathogenesis
Susan L WelkosG O Nelson

Abstract

Inflammatory responses were compared in vivo, and host phagocytic cell functions compared in vitro, of mice resistant (CBA/J) and susceptible (A/J) to lethal infection with the Sterne strain of Bacillus anthracis. Polymorphonuclear leukocyte (PMN) and macrophage responses at the initial site of infection were slower in A/J mice than in CBA/J mice. Whereas in A/J mice, the number of PMN ultimately responding to infection was equal to, or greater than, that in CBA/J mice, fewer macrophages accumulated. A/J mice failed to clear relatively low doses of the organisms and died. In vitro, chemotactic responses to both serum- and bacteria-derived attractants were similar for macrophages from A/J and CBA/J mice but were reduced for PMN from A/J mice. PMN and macrophages from the two mouse strains phagocytosed and killed spores in vitro to a similar extent, although killing by A/J PMN could be blocked by prior uptake of large numbers of killed spores. Thus susceptibility to lethal infection with Sterne strain correlated with the delayed influx (PMN) and reduced accumulation (macrophages) of phagocytes at the initial site of infection, but not with defective in vitro uptake or killing of spores.

References

Jan 1, 1979·Current Topics in Cellular Regulation·E Schiffmann, J I Gallin
Mar 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·E SchiffmannS M Wahl
Mar 1, 1986·Infection and Immunity·S L WelkosP H Gibbs
Jun 1, 1986·Infection and Immunity·P P SinghR F Mortensen
Jan 1, 1988·Microbial Pathogenesis·S L Welkos, A M Friedlander
Jul 1, 1986·Journal of Leukocyte Biology·A RotE J Leonard
May 1, 1973·The Journal of Experimental Medicine·E H Vallota, H J Müller-Eberhard
Feb 1, 1968·The Journal of Experimental Medicine·C G Cochrane, H J Müller-Eberhard
Aug 1, 1980·The Journal of Clinical Investigation·D E Van Epps, M L Garcia
Jan 1, 1980·Current Topics in Cellular Regulation·J E Niedel, P Cuatrecasas
Nov 25, 1983·Journal of Immunological Methods·R M FauveB Hevin
Jan 1, 1983·Infection and Immunity·J D Ristroph, B E Ivins
Jun 1, 1984·Vaccine·P HambletonJ Melling
Jan 1, 1980·The Journal of Clinical Investigation·M A Horwitz, S C Silverstein
Jun 1, 1982·Infection and Immunity·K M Nugent, E L Pesanti
May 1, 1963·Genetics·L A HERZENBERGL T ROSENBERG
Nov 1, 1964·The Journal of Experimental Medicine·B CINADERA C WARDLAW

❮ Previous
Next ❯

Citations

Mar 14, 2002·Biochemical and Biophysical Research Communications·John KalnsJohnathan Kiel
Sep 25, 2008·Journal of the National Cancer Institute·Zhiyu LiSavio L C Woo
Dec 28, 2007·Antimicrobial Agents and Chemotherapy·Angelo ScorpioArthur M Friedlander
Nov 3, 2010·Infection and Immunity·Amy JenkinsSusan Welkos
Sep 14, 2002·Infection and Immunity·John A W Ireland, Philip C Hanna
Jun 24, 2003·Infection and Immunity·Matthew A Weiner, Philip C Hanna
Oct 27, 2004·Infection and Immunity·Alison K PickeringTod J Merkel
Nov 23, 2006·Journal of Bacteriology·Rebecca GiornoAdam Driks
Jan 24, 2006·Journal of Bacteriology·Eric P SkaarOlaf Schneewind
Nov 18, 2005·PLoS Pathogens·Anne Mayer-SchollArturo Zychlinsky
Oct 15, 2009·Future Microbiology·Theodor Chitlaru, Avigdor Shafferman
May 15, 2013·EMBO Molecular Medicine·Franz Bauernfeind, Veit Hornung
Aug 6, 2011·Microbes and Infection·Christopher K CoteJoel Bozue
Mar 31, 2009·Microbial Pathogenesis·Christopher PremanandanAndrew J Phipps
Dec 4, 2015·MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports·William A BowerUNKNOWN Centers for Disease Control and Prevention (CDC)
Jan 25, 2007·International Journal of Experimental Pathology·Timothy S BischofPeter G Sohnle
Nov 1, 2006·Molecular Microbiology·Luciano A Marraffini, Olaf Schneewind
May 8, 2008·International Journal of Experimental Pathology·Beth L HahnPeter G Sohnle
Mar 5, 2011·Molecular Microbiology·So-Young OhOlaf Schneewind
Nov 13, 2009·Molecular Microbiology·Justin Kern, Olaf Schneewind
Oct 25, 2013·Cellular Microbiology·Zachary P WeinerIan J Glomski
Nov 28, 2012·Microbial Pathogenesis·Jared D HeffronSusan L Welkos
Aug 5, 2016·Molecular Microbiology·Jennifer M ScarffAlison D O'Brien
Jul 27, 2010·Veterinary Pathology·N A Twenhafel
Apr 4, 2018·Infection and Immunity·Yuliya I SeldinaAlison D O'Brien
Jan 1, 2014·Antimicrobial Agents and Chemotherapy·Johanna RiveraArturo Casadevall
Aug 30, 2013·Expert Review of Vaccines·Manpreet KaurRakesh Bhatnagar
Dec 2, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jill K TerraKenneth A Bradley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.